Navigation Links
New test for breast cancer will help guide treatment choices
Date:2/9/2009

SALT LAKE CITY One in eight women in the United States will receive a diagnosis of breast cancer in their lifetime, and it is the second leading cause of cancer-related death in women. Now a new test will help physicians determine the best possible treatment for each patient.

"Our research shows that there is a subset of women who can be cured without getting any treatment at all, other than a lumpectomy," explains Philip Bernard, M.D., an investigator at the University of Utah's Huntsman Cancer Institute and one of the senior authors on a multicenter study published in the Feb. 9 issue of the Journal of Clinical Oncology. "In women whose tumors have spread, we can predict with very high accuracy which women are going to respond to chemotherapy and which type of chemotherapy will work."

Only recently have scientists known that there are different breast cancer subtypes that lead to differences in outcome. The group narrowed down 50 genes that play an important role in identifying subtypes of breast cancer. By measuring the expression level of these genes in the tumors, they could determine how each individual will respond to standard therapies.

"This will give women peace of mind knowing that we're diagnosing cancer more accurately than ever before. We can tell them if they are likely to benefit from chemotherapy. If chemo isn't going to be beneficial, we shouldn't be giving it," Bernard says.

The research translates into a simple test that will be available nationwide this summer. The test has been validated on thousands of women with breast cancer and has shown to be useful in many different clinical situations.

Based on the type of tumor, doctors now will be able to prescribe only the treatment that will be most beneficial. For some patients that could mean no chemotherapy at all. For others it will mean targeted treatments that work best for that patient, and they will no longer have to endure nee
'/>"/>

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Statin therapy ineffective in breast cancer prevention
2. Hispanic women and breast cancer: An understudied group
3. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
4. New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome
5. Fast-food diet cancels out benefits of breastfeeding in preventing asthma
6. Facebook flack regarding breastfeeding mothers
7. HWI scientist first in world to unravel structure of key breast cancer target enzyme
8. Team finds breast cancer gene linked to disease spread
9. Benefits of breastfeeding outweigh risk of infant exposure to environmental chemicals in breastmilk
10. Breast cancer genome shows evolution, instability of cancer
11. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
Breaking Biology News(10 mins):PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... , , , ... Frost & Sullivan European Border Security Product Innovation Award is ... Border Control systems. The award recognises the company,s expertise in ... value-added products to end users. , (Logo: ...
... GenWay Biotech, Inc. GenWay Clinical Laboratory, San Diego, ... College of American Pathologists (CAP), based on results ... The laboratory,s director was advised of this national ... services being provided." GenWay Biotech Inc. GenWay Clinical ...
... , This release is available in German ... limited use in predicting the future distribution of mammals. This ... of 140 indigenous European mammals. The researchers analysed data on ... the phylogenetic information of the species. Judging by the large ...
Cached Biology News:Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Species distribution models are of only limited value for predicting future mammal distributions 2
(Date:11/18/2014)... 2014 pH measurement and control is ... pharmaceutical, chemical, and food and beverage industries. But what ... how do pH sensors work? METTLER TOLEDO has produced ... process industries with these questions and more. , METTLER ... the process industries. The actual sensor, the pH electrode, ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) and ... with researchers at Georgia Institute of Technology, Clark ... USDA’s Forest Products Laboratory to develop ultra-strong, lightweight ... a rapidly emerging high performance nanomaterial extracted from ... replace heavy steel structures within cars, such as ...
(Date:11/18/2014)... Array Architects is proud of a ... the nation's hospitals and health systems. It is a ... their careers to the advancement of both the healthcare ... respective field, Laura Silvoy has been chosen to share ... Simulation Conference. , Laura will present her Process ...
(Date:11/18/2014)... , Nov. 18, 2014  Great Basin Scientific, Inc. ... announced that the management will host a conference call and ... development programs on Thursday, Nov. 20, at 4:30 pm EST ... have made since the Company,s recent IPO and would like ... Basin,s management," said Ryan Ashton , President and Chief ...
Breaking Biology Technology:pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2
... Group 13th Annual Healthcare Conference, SAN DIEGO, ... device company focused on the treatment of cardiac,arrhythmias, ... Cryoablation,System and its next generation ablation catheter, Quantum, ... CryoCor,s products will,be located at Booth 801., ...
... Inc.,(CTI) (Nasdaq: CTIC ; MTAX: CTIC) announced today ... new common shares. This share issue will equate to,approximately ... to close on Wednesday, January 16, and to raise ... Societe Generale,pursuant to the Step-Up Equity Financing Agreement entered ...
... The Greater Baltimore,Committee is seeking nominations for the ... held on Tuesday, March 18, 2008. Those,interested in ... visit, http://www.gbc.org ., The four award categories ... Bioscience, and President,s Award. Nominators will,be asked to ...
Cached Biology Technology:CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium 2CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium 3Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale 2